Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten
- 15 April 2024
- journal article
- letter
- Published by Elsevier in Heart Rhythm
- Vol. 21 (10) , 2065-2067
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Mavacamten Treatment for Symptomatic Obstructive Hypertrophic CardiomyopathyJACC: Heart Failure, 2024
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyJACC, 2022
- Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF ScoreCirculation: Arrhythmia and Electrophysiology, 2021
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome predictionThe Lancet, 2019